A molecule that re-educates, rather than punishes
Oleiletanolamide is a naturally occurring compound without psychoactive effects that reduced alcohol-seeking behavior in female rats without causing anxiety. Current alcohol treatments rely on aversion tactics causing nausea, vomiting, and liver damage; this molecule works by re-educating brain reward circuits instead.
- Oleiletanolamida reduced alcohol-seeking in 48 female Wistar rats without increasing anxiety
- Current treatments cause nausea, vomiting, insomnia, and liver damage; this molecule is naturally produced by the human body
- Over 3 million people die annually from alcohol-related causes; 7 of 10 Colombian adults drink regularly
- Women develop alcohol dependence faster and at lower doses than men due to lower enzyme activity and higher body fat
Colombian researchers discovered that oleiletanolamide, a naturally produced body molecule, reduces compulsive alcohol-seeking behavior in rats, offering a safer alternative to conventional addiction treatments with fewer side effects.
At the National University of Colombia, researchers have identified a naturally occurring molecule that appears to quiet the brain's compulsive drive toward alcohol—without the nausea, liver damage, and cognitive fog that plague existing treatments. The molecule is called oleiletanolamida, and in recent experiments with female rats, it demonstrated a striking ability to reduce the obsessive seeking of alcohol, suggesting a fundamentally different approach to one of the world's most normalized and destructive addictions.
Conventional medications for alcohol dependence—disulfiram, naltrexone, acamprosato—work largely through punishment. They make drinking unpleasant. Patients experience nausea, vomiting, insomnia, dizziness, sometimes liver injury. The drugs don't eliminate desire; they simply attach suffering to its pursuit. Oleiletanolamida operates on a different principle. It is a compound the human body produces naturally, particularly in the gastrointestinal tract, where it regulates appetite and satiety. It belongs to the endocannabinoid family but carries none of the psychoactive effects or addiction risk of cannabis. Early evidence suggests it works by recalibrating the brain's reward circuits—not punishing the drinker, but gently redirecting the neural pathways that drive compulsive consumption.
The discovery emerged unexpectedly from research initially focused on cannabidiol, another cannabis-derived compound. As Juan Santiago Bermúdez, a toxicology master's student at the university, and his advisors Gustavo González Cuevas and William Giovanni Quevedo Buitrago explored the endocannabinoid system, they found that oleiletanolamida—a relative of anandamida, another naturally produced brain chemical—held particular promise for modulating alcohol dependence. The team conducted their experiments on 48 female Wistar rats, some with prior alcohol exposure and some without. After the animals developed dependence through controlled ethanol administration, researchers gave half of them oleiletanolamida. The treated rats showed markedly less interest in returning to the location where they had previously encountered alcohol. Crucially, anxiety tests revealed no increase in stress or fear—the reduction in alcohol-seeking was not driven by dread or avoidance, but by a genuine shift in the brain's perception of reward.
The choice to focus on female rats was deliberate and addresses a significant gap in addiction science. Women metabolize alcohol differently than men. Their bodies produce less of the enzyme alcohol dehydrogenase, which breaks down ethanol, meaning alcohol lingers longer in their systems. They carry a higher proportion of body fat, which further concentrates the drug. The neurological damage is more severe, and dependence can develop at lower doses and faster timelines. Yet most addiction research has historically centered on males. Bermúdez and his colleagues recognized that any treatment claiming to be broadly applicable must account for these physiological realities.
The scale of the problem is staggering. More than three million people die annually worldwide from alcohol-related causes—five percent of all deaths. In Colombia alone, seven of every ten adults drink regularly. The damage accumulates silently: liver disease, cardiovascular injury, immune system collapse, brain atrophy. Alcoholism is so woven into social fabric that its costs are often invisible until they are catastrophic. A molecule that could interrupt the cycle of craving without poisoning the body in the process would represent a genuine shift in how addiction is treated.
Bermúdez notes that oleiletanolamida shows promise beyond alcohol. Because it naturally regulates hunger and satiety, it might also help people struggling with obesity—another condition where existing medications carry significant side effects. But the immediate significance lies in its potential to transform addiction treatment from a punitive model to a restorative one. Rather than making patients suffer until they stop wanting to drink, oleiletanolamida appears to gently rewire the brain's motivational architecture. The next phase will be moving from rats to human trials, a process that typically takes years. But the foundation has been laid: a naturally occurring, well-tolerated compound that addresses addiction not through aversion but through re-education of the neural circuits that drive compulsive behavior.
Citações Notáveis
It is a compound very promising as a mediator of hunger and anxiety, so it could also help people with obesity— Juan Santiago Bermúdez, toxicology researcher
It is an alternative that does not punish, but re-educates the brain circuits— Juan Santiago Bermúdez
A Conversa do Hearth Outra perspectiva sobre a história
Why focus the study on female rats when most addiction research uses males?
Because women's bodies handle alcohol fundamentally differently. They have less of the enzyme that breaks it down, more body fat where alcohol concentrates, and they develop dependence faster at lower doses. If you're going to propose a treatment, you need to understand how it works across different physiologies.
So this molecule—oleiletanolamida—it's something the body already makes?
Yes, naturally in the gut. It regulates appetite and fullness. The insight was recognizing it might also regulate the brain's reward circuits around alcohol. It's not foreign; it's not forcing the body into an unnatural state.
How is that different from current medications?
Current drugs mostly work through punishment. They make drinking unpleasant—nausea, liver damage, insomnia. The person still wants alcohol; the drug just attaches suffering to it. Oleiletanolamida seems to actually change what the brain finds rewarding about alcohol in the first place.
Did the rats still feel anxious or stressed when they stopped seeking alcohol?
No. That was crucial to the experiment. The researchers tested for anxiety specifically and found none. The reduction in alcohol-seeking wasn't driven by fear or dread. It was a genuine shift in motivation.
What happens next?
Human trials, eventually. But that takes years of regulatory work. For now, the team has shown the mechanism works in a living system without obvious harm. That's the foundation.
Why does it matter that this is naturally produced by the body?
Because it suggests the body already has the capacity to regulate this. We're not introducing something alien; we're amplifying something that's already there. That's why the side effect profile looks so clean.